- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02606565
Efficacy of Umbilical Cord Cleansing With a Single Application of 4% Chlorhexidine for the Prevention of Newborn Infections in Uganda: a Randomized Controlled Trial
Acceptability and Efficacy of Umbilical Cord Cleansing With 4% Chlorhexidine for the Prevention of Newborn Infections in Lira District, Northern Uganda: A Randomised Controlled Trial
Background: Nearly all the yearly 3.3 million neonatal deaths occur in low and middle income countries. Infections, including those affecting the umbilical cord (omphalitis) are a significant factor in approximately a third of these deaths. In fact, the odds of all-cause mortality are 46% higher among infants with umbilical cord infection than those without infection. Five large randomized controlled trials in Asia and Sub-Saharan Africa have examined the effect of multiple applications (for at least 7 days) of 4% chlorhexidine (CHX) on the umbilical cord on omphalitis and neonatal death. These studies show a consitent positive effect of multiple applications on omphalitis but not on neonatal mortality. Whereas there is mounting evidence for the effect of 7 day chlorhexidine application, there is no data from Africa and only one study from Asia that examines the effect of a single application of CHX as soon as possible after birth. In this single Asian study, CHX led to a reduction in the risk of mild-moderate omphalitis and neonatal death. It is important, in an African setting to explore the effect of a single application, which is programmatically much simpler to implement than daily application for 7 days. Therefore, the investigators' study will compare umbilical cord cleansing with a single application of 4% chlorhexidine at birth with dry cord care in both community and facility births on omphalitis and severe illness in the neonatal period.
Methods: The chlorhexidine study is a community based, individually randomised controlled trial conducted on 4,760 mother-infant pairs in Uganda. The primary outcomes are severe illness and umbilical cord infection (omphalitis). Severe illness is defined as any illness associated with at least one of the following danger signs observed by study research assistants: inability to drink or breastfeed or (a history of) convulsions, lethargy or unconsciousness, vomiting of all feeds, and/or results in hospitalization and/or results in death.
Discussion: This study will provide novel evidence, from a Sub-Saharan African setting of the effect of umbilical cord cleansing with a single application of 4% chlorhexidine at birth in both community and facility births.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Victoria Nankabirwa, MD, MPH, PhD
- Phone Number: +256755757460
- Email: nankabirwav@gmail.com
Study Locations
-
-
-
Kampala, Uganda
- Recruiting
- Health Centers in Mukono and Kampala districts
-
Contact:
- Victoria Nankabirwa, MBChB, MPH, PhD
- Phone Number: +256755757460
- Email: nankabirwav@gmail.com
-
Principal Investigator:
- Victoria Nankabirwa, PhD
-
Principal Investigator:
- Halvor Sommerfelt, PhD
-
Sub-Investigator:
- Grace Ndeezi, PhD
-
Sub-Investigator:
- James Tumwine, PhD
-
Sub-Investigator:
- Thorkild Tylleskar, PhD
-
Contact:
- Josephine Tumuhamye, BBLT, MICM
- Phone Number: 0702063261
- Email: tphynne@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newborns weighing 1.5kg or more at birth
- Newborns born to mothers whose HIV I status is negative
Exclusion Criteria:
- Newborns with severe congenital anomalies
- Newborns with infection of the umbilical cord at birth
- Twins or triplets
- Severely ill infants requiring hospitalization immediately after birth
- Children of mothers who cannot appropriately give consent within 12 h of birth
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm: 4% chlorhexidine
Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
|
See previous description
|
No Intervention: Control arm: Dry cord care
Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of infants with severe illness
Time Frame: First 28 days of life
|
Severe illness will be defined as an acute illness that is associated with any of the following danger signs observed or verified by a study clinician: inability to feed or vomiting of everything and unable to keep anything down, lethargy or unconsciousness, severe lower chest in-drawing, axillary temperature of ≥38.0 degrees Celsius or <35.5 degrees Celsius, grunting, cyanosis, convulsions or a history of convulsions, and/or results in hospitalization and/or results in death.
Hospitalization and death resulting from violent injury or burns will not contribute to the severe illness definition.
|
First 28 days of life
|
Proportion of infants with omphalitis
Time Frame: First 28 days of life
|
This outcome will be recorded as present or absent based on specific signs.
These include: pus, redness (inflammation) and swelling (oedema) of the cord stump and the surrounding skin at its base.
Swelling and redness will be further broken down into: none, mild, moderate and severe.
No swelling or redness will be the absence of visible swelling or redness; mild swelling or redness as that limited to the cord stump only; moderate swelling or redness as that extending less than 2cm onto the abdominal skin at the base of the stump and severe swelling or redness as extending ≥2cm into the abdominal skin at the base of the stump.
Pus will be defined as either present or absent.
Cord infection will then be defined based on combinations of these recorded signs and their severity into four categories as follows: 1) redness extending to skin or pus, 2) moderate or severe redness, 3) moderate or severe redness with pus, or severe redness alone and 4) Severe redness with pus.
|
First 28 days of life
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Death
Time Frame: First 28 days of life
|
First 28 days of life
|
Adverse events
Time Frame: First 28 days of life
|
First 28 days of life
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Victoria Nankabirwa, MD, MPH, PhD, Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University
Publications and helpful links
General Publications
- Imdad A, Bautista RM, Senen KA, Uy ME, Mantaring JB 3rd, Bhutta ZA. Umbilical cord antiseptics for preventing sepsis and death among newborns. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD008635. doi: 10.1002/14651858.CD008635.pub2.
- Nankabirwa V, Tylleskar T, Tumuhamye J, Tumwine JK, Ndeezi G, Martines JC, Sommerfelt H. Efficacy of umbilical cord cleansing with a single application of 4% chlorhexidine for the prevention of newborn infections in Uganda: study protocol for a randomized controlled trial. Trials. 2017 Jul 12;18(1):322. doi: 10.1186/s13063-017-2050-0.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-118
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Omphalitis
-
Aga Khan UniversityJohn Snow, Inc.Completed
-
University of New MexicoUniversity of NairobiTerminated
-
Nantes University HospitalTerminated
-
The Hospital for Sick ChildrenAga Khan University; Aga Khan Health Services; The Aga Khan FoundationRecruiting
-
Johns Hopkins Bloomberg School of Public HealthInternational Centre for Diarrhoeal Disease Research, Bangladesh; Government... and other collaboratorsCompletedInfection | OmphalitisBangladesh
-
Boston UniversityBill and Melinda Gates Foundation; Thrasher Research FundCompleted
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Annamalai University; Ministry of Health and...CompletedOmphalitis | Neonatal Mortality | Cord CareTanzania
-
Sheikh Zayed Federal Postgraduate Medical InstituteCompletedOmphalitis | Neonatal SepsisPakistan
-
Yale UniversityUniversity of California, San Diego; Inter-American Development BankCompletedDiarrhea | Hypothermia | Preterm Delivery | Upper Respiratory Infection | OmphalitisUnited States, Honduras
-
Aga Khan UniversityDepartment for International Development, United KingdomCompletedPneumonia | Sepsis | Eclampsia | Respiratory Distress Syndrome | Postpartum Hemorrhage | Omphalitis | Birth Asphyxia | Puerperal SepsisPakistan
Clinical Trials on Intervention arm: 4% chlorhexidine
-
Columbia UniversityOrthopaedic Scientific Research Foundation IncCompletedInfection | Spinal InjuriesUnited States
-
Hôpital NOVOCompletedHemiplegia and/or Hemiparesis Following StrokeFrance
-
UConn HealthNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Centre Leon BerardNational Cancer Institute, France; Fondation de France; Cancéropôle Lyon Auvergne... and other collaboratorsCompletedImpact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy (PASAPAS)Breast Cancer | Adequate Physical ConditionFrance
-
Jonsson Comprehensive Cancer CenterAmerican Cancer Society, Inc.Completed
-
Dr Thomas DiPetrilloMemorial Hospital of Rhode IslandCompletedLung CancerUnited States
-
Heart of England NHS TrustAstraZenecaUnknown
-
Gia MuddNational Institute of Nursing Research (NINR); National Institutes of Health...CompletedCardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Reduction BehaviorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHPV | Related Malignancy | Related CarcinomaUnited States
-
Medline IndustriesCompleted